Tesaro

Xencor sells ex-lead drug to Tesaro founder in backloaded deal

Almost three years after deciding to partner in the wake of a failed trial, Xencor has offloaded the drug to Zenas in a deal worth up to $480 million.

Nick Paul Taylor Nov 22, 2021 8:45am

AbbVie, Roche top data transparency list in new Yale report

Jul 21, 2021 10:15am

GSK posts middling data from PD-1 Tesaro buyout drug

Apr 24, 2020 8:35am

GlaxoSmithKline talks up new R&D focus, keeps mum on M&A

Feb 6, 2020 7:34am

JPM Tuesday: Pfizer's pipeline, 2020's bolt-on deals

Jan 15, 2020 7:50am

ESMO: AbbVie's PARP inhibitor veliparib finally gets a win

Sep 29, 2019 4:16am